The orally-active P2X3 receptor antagonist, also known as BAY1817080, hit the main objective of the study, which was to reduce the average hourly cough frequency based on 24-hour sound recordings ...
Both drugs are selective P2X3 receptor antagonists, designed to inhibit a hypersensitisation of the cough reflex in people struggling with chronic cough. At the moment there are no approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback